Advanced in Teratoma of the Mediastinum

Robert A. Huddart

Institute Of Cancer Research And Royal Marsden Hospital FT, 
Sutton Upon Derwent, ENG, GB 
Advanced in Teratoma of the Mediastinum
Institute Of Cancer Research And Royal Marsden Hospital FT, 
Sutton Upon Derwent, ENG, GB 
OverviewLocationsClinical Research

Overview

Robert Huddart practices in Sutton Upon Derwent, United Kingdom. Mr. Huddart is rated as an Advanced expert by MediFind in the treatment of Teratoma of the Mediastinum. His top areas of expertise are Muscle Invasive Bladder Cancer, Testicular Cancer, Bladder Cancer, Orchiectomy, and Cystectomy.

His clinical research consists of co-authoring 218 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles and participated in 1 clinical trial in the study of Teratoma of the Mediastinum.

Gender
Male

Locations

Institute Of Cancer Research And Royal Marsden Hospital FT, Sutton Upon Derwent, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug, Procedure
Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate
Study Phase: Phase 3
A Randomised Phase II Trial of Adaptive Image Guided Standard or Dose Escalated Tumour Boost Radiotherapy in the Treatment of Transitional Cell Carcinoma of the Bladder
A Randomised Phase II Trial of Adaptive Image Guided Standard or Dose Escalated Tumour Boost Radiotherapy in the Treatment of Transitional Cell Carcinoma of the Bladder
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2020
Intervention Type: Radiation
Study Phase: Phase 2
A Randomized Phase II Trial of Carboplatin and Gemcitabine +/- Vandetanib in First Line Treatment of Advanced Urothelial Cell Cancer in Patients Who Are Not Suitable to Receive Cisplatin
A Randomized Phase II Trial of Carboplatin and Gemcitabine +/- Vandetanib in First Line Treatment of Advanced Urothelial Cell Cancer in Patients Who Are Not Suitable to Receive Cisplatin
Enrollment Status: Completed
Publish Date: May 16, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

217 Total Publications

HER2 and urothelial carcinoma: current understanding and future directions.
HER2 and urothelial carcinoma: current understanding and future directions.
Journal: Nature reviews. Urology
Published: July 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Huddart's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile